[CAS NO. 1429024-58-7] STL1267
PRODUCTS SPECIFICATIONS [1429024-58-7]
DESCRIPTION [1429024-58-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 322.75 |
| Molecular Formula | C17H11ClN4O |
| SMILES | ClC1=NN=C2C=CC(OC3=C(C4=CC=CC=C4)C=CC=C3)=NN12 |
Summary
IC50 & Target
K i : 0.16 µM (REV-ERBα) [1]
In Vitro
STL1267 (5 µM; 24 h) decreases the expression of BMAL1 and increases the gene expression of Mtnd1, Mtco1, Vicad, Lcad, Scad, Lkb1, Sirt1, Nampt, Ppargc1a in HepG2 cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | HepG2, C2C12 cells |
| Concentration: | 0-20 µM |
| Incubation Time: | 24 h |
| Result: | Showed no adverse effects on cell viability up to the maximum dose examined 20 µM. |
RT-PCR [1]
| Cell Line: | HepG2 cells |
| Concentration: | 5 µM |
| Incubation Time: | 24 h |
| Result: | Decreased the gene expression of BMAL1, increased the gene expression of Mtnd1, Mtco1, Vicad, Lcad, Scad, Lkb1, Sirt1, Nampt, Ppargc1a. |
In Vivo
STL1267 (50 mg/kg; i.p.; once) inhibits Bmal1 expression in mouse [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 6-8 weeks, male C57Bl/6 J mice [1] |
| Dosage: | 50 mg/kg |
| Administration: | I.p.; once |
| Result: | Showed a plasma half-life of 1.6 h, effectively suppressed BMAL1 expression in the liver at 12 h post-administration. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.